US equities |
MU $795.41 ▲+0.02% SNDK $1,037.40 ▲+0.00% NVDA $200.13 ▲+0.00% AMD $488.78 ▲+0.00% SPCX $135.92 ▲+0.00% TSLA $385.19 ▲+0.00% AMZN $266.03 ▲+0.00% SKHY $143.07 ▲+0.00%
FinancialContent

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.290 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Breaking Down Ardelyx: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism ↗
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah. 
Via Stocktwits
News headline image
Ardelyx Tops Estimates as Sales Surge ↗
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah. 
Via The Motley Fool
News headline image
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday? ↗
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >